Study of OCT Peripapillary Angiography in Patients With Advanced Glaucoma (NCT06274593) | Clinical Trial Compass
RecruitingNot Applicable
Study of OCT Peripapillary Angiography in Patients With Advanced Glaucoma
France50 participantsStarted 2024-04-27
Plain-language summary
Glaucoma is a chronic disease of the optic nerve, characterized by progressive loss of nerve cells in the retina, leading to progressive loss of peripheral and central vision. There are in fact several types of glaucoma, which is the world's second leading cause of blindness after cataracts, and the leading cause of irreversible blindness.
To date, to our knowledge, there is no work analyzing the progression of angiographic OCT in patients with glaucoma.
The main aim of this study is to compare the 3-year progression rate of 3 examinations in advanced glaucoma patients: one functional (visual field) and two anatomical (OCTa and OCTrnfl).
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Men and women aged 18 and over
* Patient with glaucoma followed in the ophthalmology department of Nantes University Hospital
* mean visual field deficit (MD) \>10dB
Exclusion Criteria:
* Retinal vascular pathology (moderate to severe non-proliferative diabetic retinopathy, complicated diabetic retinopathy, OVCR/OBVR, OACR/OBAR, NOIAA...) Non-glaucomatous optic neuropathy, neurological pathology leading to visual field deficit (stroke with HLH, quadranopsia, chiasmatic Sd...)
* PPR (retinal PanPhotocoagulation), retinal cerclage
* Retinal pathology leading to visual field impairment (e.g. retinitis pigmentosa)
* AMD and other macular pathologies that can lead to central visual field deficits
* Significant environmental disorders impairing retinal imaging (e.g. active uveitis, dense cataract)
* Loss of fixation point preventing visual field formation Pregnant or breast-feeding women
* Protected adults under guardianship or curatorship
* with unreliable visual fields (false positives and false negatives \> 33%)
* with an uninterpretable OCTrnfl or OCTa (artifact, low quality score)
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Compare the progression of vascular density (VD) in advanced glaucoma patients.
Timeframe: 3 year
2
Compare the progression of peripapillary retinal nerve fiber (RNFL) thickness) in advanced glaucoma patients.
Timeframe: 3 year
3
Compare the progression of visual field in advanced glaucoma patients.